Post-infection immunity provides excellent protection from COVID-19 ICU hospitalization during Delta and Omicron waves

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F22%3AA2302GYW" target="_blank" >RIV/61988987:17110/22:A2302GYW - isvavai.cz</a>
Alternative codes found
RIV/00216208:11320/23:10452130
Result on the web
<a href="https://www.webofscience.com/wos/woscc/full-record/WOS:000857358900001" target="_blank" >https://www.webofscience.com/wos/woscc/full-record/WOS:000857358900001</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/23744235.2022.2125575" target="_blank" >10.1080/23744235.2022.2125575</a>

Result language
angličtina
Original language name
Post-infection immunity provides excellent protection from COVID-19 ICU hospitalization during Delta and Omicron waves
Original language description
A recent Estonian report in your journal investigated the anti-SARS RBD-IgG levels of 123 patients classified according to the severity of COVID-19 [1]. At 1-year follow-up, patients with severe disease had higher antiSARS RBD levels compared to patients with a mild disease course. In most patients who subsequently received a single dose of the Pfizer-BioNTech or AstraZeneca vaccine, antibody levels increased significantly. Hence, the authors recommended a single dose of COVID vaccine for convalescent patients, especially those after a mild disease [1].
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30303 - Infectious Diseases

Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)